About this item:

207 Views | 129 Downloads

Author Notes:

Corresponding Author: Emory Vaccine Center 954 Gatewood Rd. Atlanta, GA 30329 Phone: 404-727-8594 cderdey@emory.edu

We thank Jinal Bhiman and Kurt Wibmer for help with preparing the figures.

Subject:

Research Funding:

CAD gratefully acknowledges the National Institutes for Health (NIH) for grants R01 AI58706 and U19 AI96187, the Rwanda Zambia HIV Research Group (RZHRG), and the International AIDS Vaccine Initiative (IAVI) for their support.

LM and PLM gratefully acknowledge funding from CAPRISA, the National Institute of Allergy and Infectious Diseases (NIAID) Center for HIV/AIDS Vaccine Immunology (CHAVI) grant AI067854, the Center for AIDS Vaccine Discovery (CAVD) of the Bill and Melinda Gates Foundation, the South African HIV/AIDS Research and Innovation Platform of the South African Department of Science and Technology and by a HIVRAD NIH grant AI088610.

CAPRISA was supported by NIAID, NIH, U.S. Department of Health and Human Services (Grant U19 AI51794).

PLM is a Wellcome Trust Intermediate Fellow in Public Health and Tropical Medicine (Grant 089933/Z/09/Z).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Immunology
  • Infectious Diseases
  • unmutated common ancestor
  • broadly neutralizing antibodies
  • HIV-1 envelope evolution
  • affinity maturation
  • long CDRH3
  • B-CELL RECEPTORS
  • BINDING-SITE ANTIBODIES
  • ENVELOPE PROTEIN
  • VACCINE DESIGN
  • GP120
  • EVOLUTION
  • VIRUS
  • RECOGNITION
  • CORRELATE
  • PATHWAYS

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection

Tools:

Journal Title:

Current Opinion in HIV and AIDS

Volume:

Volume 9, Number 3

Publisher:

, Pages 210-216

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Purpose of Review: Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins. A current priority is to understand how bnAbs are generated during natural infection, and translate this information into immunogens that can elicit bnAb following vaccination. RECENT FINDINGS: Strain-specific neutralizing antibodies can acquire broad neutralizing capacity when the transmitted/founder Env or a specific Env variant is recognized by an unmutated rearranged germline that has the capacity to develop bnAb-like features. This event could be relatively infrequent, as only certain germlines appear to possess inherent features needed for bnAb activity. Furthermore, the glycosylation pattern and diversity of circulating HIV-1 Envs, as well as the state of the B-cell compartment, may influence the activation and maturation of certain antibody lineages. SUMMARY: Collectively, studies over the last year have suggested that the development of HIV-1 Env immunogens that bind and activate bnAb-like germlines is feasible. However, more information about the features of Env variants and the host factors that lead to breadth during natural infection are needed to elicit bnAbs through immunization.

Copyright information:

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Export to EndNote